Monoclonal Antibody Treatment for Certain Cases of COVID-19 Now Available
Health Care Medical Infusion Specialties is providing monoclonal antibody treatment (combination casivirimab and imdevimab) to patients who have been exposed or contracted COVID-19 and meet the criteria set forth by the Food and Drug Administration’s Emergency Use Authorization (EUA). This monoclonal antibody treatment has been shown to significantly reduce the viral load of COVID-19 and patients do not need to be vaccinated to receive it.
To schedule your treatment and determine if you may qualify, please call us at (769) 233-8484. We will be open Monday – Friday from 8 a.m. – 5 p.m. and 10 a.m. – 3 p.m. on Saturdays for monoclonal antibody treatments and can also provide infusion treatments in-home, should a patient require one.
More Information on Monoclonal Antibody Treatment
Adults and pediatric individuals (older than 12 years and weighing more than 40 kg) who meet the following criteria can be treated with this monoclonal antibody treatment after contracting or being exposed to COVID-19:
o Those who are at high risk for progression to severe COVID-19 and are not fully vaccinated
OR
o Those who are not expected to have an adequate immune response to COVID-19 vaccination
AND
o Those who have been exposed to an individual infected with COVID-19 consistent with close contact criteria per The Centers of Disease Control and Prevention
o Those who are at high risk of exposure to an individual infected with COVID-19 because of an occurrence of COVID-19
Older adults, those with underlying medical conditions (like chronic lung diseases, heart conditions, diabetes, smoking, etc.) and those pregnant and recently pregnant are at a higher risk for severe illness. Prophylactic treatment for exposure requires an order from your physician.
Casirivimab and imdevimab monoclonal antibody treatment can be administered as an infusion or subcutaneous injection. Intravenous infusion is strongly recommended for treatment of active infection. Subcutaneous injection is an alternative route of administration when intravenous infusion is not feasible and would lead to delay in treatment.
Health Care Medical Infusion Specialties has provided infusion care and durable medical equipment to Mississippians for more than 20 years. The administration of this monoclonal antibody treatment will be handled by its highly skilled clinical staff and onsite pharmacy to ensure compliance and quality care.
Treatment with casirivimab and imdevimab is not a substitute for vaccination against COVID-19. This treatment is also not authorized for pre-exposure administration for prevention of COVID-19.
Additional Resources:
https://msdh.ms.gov/msdhsite/_static/resources/15384.pdf